CRL | tickerfilter.com

Fundamental analysis

49%

Profitability 61%

Dept financing 22%

Liquidity 22%

Performance 51%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.27%

1 Month

-27.46%

3 Months

-30.86%

6 Months

-38.53%

1 Year

-50.60%

2 Year

-37.59%

Key data

Stock price

$114.66

P/E Ratio

428.75

DAY RANGE

$112.12 - $115.24

EPS

$2.55

52 WEEK RANGE

$91.86 - $254.15

52 WEEK CHANGE

-$50.60

MARKET CAP

9.520 B

YIELD

N/A

SHARES OUTSTANDING

51.631 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

1.33

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,936,775

AVERAGE 30 VOLUME

$2,569,458

Company detail

CEO: James C. Foster
Region: US
Website: criver.com
Employees: 21,400
IPO year: 2000

Issue type: Common Stock
Market: NYSE
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services. The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies. The Manufacturing segment provides in vitro testing of sterile and non-sterile pharmaceuticals and consumer products.

CRL - CHARLES RIVER LABORATORIES INTERNATIONAL, INC.